**P636**

**HIGH DIVERSITY OF NEISSERIA GONORRHOEAE IN GERMANY REVEALED BY MOLECULAR TYPING USING NG-MAST (2014–17)**

Sebastian Banhart, Tanja Pila, Thalea Tammenga, Sandra Dudareva, Eva Guhl, Ingeborg Graber, Volunne Bremer, Peter Kohl, Susanne Buder, Klaus Jansen, Dagmar Heuer, Robert Koch Institute, Unit for Sexually Transmitted Bacterial Infections, Berlin, Germany; Robert-Koch-Institute, Unit 34: HIV/AIDS, STI and Blood-borne Infections, Berlin, Germany; Robert Koch Institute, Infectious Disease Epidemiology, Berlin, Germany; German Concilary Laboratory for Gonococci, Department of Dermatology and Venerology, Vivantes Hospital, Berlin, Germany; Robert Koch Institute, Berlin, Germany; Robert Koch Institute, Sexually Transmitted Bacterial Pathogens, Berlin, Germany

Background Neisseria gonorrhoeae (NG) infections are not reportable in Germany. The Gonococcal Resistance Network (GORENET) is a laboratory network to monitor antimicrobial resistance (AMR) in Germany, linking data from sequence typing to epidemiological data. We described prevalence of gonococcal sequence types in Germany and associations to AMR to improve future treatment and prevention strategies.

**Methods** NG isolates collected between April 2014 and December 2017 were tested by E-test and sequence typed by NG multiantigen sequence typing (NG-MAST). For sequence typing, DNA was extracted and internal fragments of *porB* and *tbpB* were amplified by polymerase chain reaction. Fragments were sequenced by Sanger sequencing and evaluated using a global database (www.ng-mast.net). Genogroups were assigned to sequence types which shared one allele and exhibited ≥99% homogeneity in the other allelic site.

**Results** 1220 isolates were sequence typed (106 in 2014, 96 in 2015, 525 in 2016, and 495 in 2017). In total, we detected 422 different sequence types that grouped into 17 genogroups. Among the most prevalent genogroups were G2400 (6.8%), G1407 (6.8%), G5441 (6.2%), G25 (5.6%), G2992 (5.5%) and G10537 (5.3%). The multi-resistant G1407 and G2400 were most prevalent in 2014 (12.4% and 10.5%, respectively) and declined to 6.1% and 7.3% in 2017. Two new genogroups, G11461 (3.6%) and G17420 (2.1%), emerged showing high prevalence in 2017 and no association to extended-spectrum cephalosporin resistance. Furthermore, a novel genogroup-association with cefixime resistance and reduced cephalosporin susceptibility was identified.

**Conclusion** From 2014 to 2017 prevalence of G1407 declined and two novel extended-spectrum cephalosporin sensitive clones G11461 and G17420 seem to have replaced the multidrug resistance clone G1407. To verify these results, continuous testing with an increased number of isolates should be performed.

**Disclosure** No significant relationships.

---

**P637**

**NEISSERIA GONORRHOEAE GENOMIC DIVERSITY IN HIGH RISK GROUPS IN SWITZERLAND**

Helena Seth-Smith*, Dianne Egli-Gány, Daniel Golparian, Valentina Dona, Andrea Endlmann, Magnus Unemo, Nicola Low, University of Bern, Institute of Social and Preventive Medicine, Bern, Switzerland; Örebro University, WHO Collaborating Centre for Gonorrhoea and other STIs, Örebro, Sweden; University of Bern, Institut für Infektionskrankheiten, Bern, Switzerland; Örebro University Hospital, Örebro, Sweden; University of Bern, Institute of Social and Preventive Medicine (ISPM), Bern, Switzerland

Background Neisseria gonorrhoeae cases are increasing in Europe, with decreasing susceptibility to first line antibiotics. Whole genome sequencing (WGS) provides detailed information about gonococcal molecular epidemiology and prediction of antimicrobial resistance (AMR), especially if linked to epidemiological data. The aim of this study was to examine molecular, clinical and social epidemiological aspects of gonorrhoea infections in Switzerland.

**Methods** In 2015–2016, we cultured urethral, cervical, vaginal, rectal, and pharyngeal specimens from patients in three clinics predominantly attended by men who have sex with men (MSM) and female sex workers (FSW). MSM also completed a sexual behaviour questionnaire. Minimal inhibitory concentrations (MIC) were assessed by Etest, interpreted using EUCAST breakpoints except azithromycin (≥2 mg/L); WGS used an Illumina Miseq.

**Results** We sequenced 140 isolates from 116 participants, MSM (107, 92%, mean age 35.8 years) and FSW (6, 5%, mean age 25.3 years). Amongst MSM, 48/105 respondents (45.7%) reported recent sex abroad. Three patients (two MSM and one FSW) carried different strains at different body sites. The isolates show large genomic diversity, with 69 NG-MAST types and 37 MLST sequence types, largely embedded within characterised European Union clusters. NG-MAST 1407 was identified in n=4 isolates from two patients (FSW, not travel-associated and MSM, sex elsewhere in Europe). Mosaic penAXXXIV was seen in these isolates, and also in an NG-MAST 13488 from an MSM, which was also not travel associated. One isolate (heterosexual male, not travel-associated) with elevated cefixime MIC (0.19 μg/ml) carried a mosaic penAX in an NG-MAST 10537 background. Ciprofloxacin resistance was seen in these six isolates, and overall in 59/140 (42%), all containing GyrA mutations S91F and D95A/G/N.

**Conclusion** Switzerland has a high diversity of circulating gonorrhoea, generally related to European clusters. Multidrug resistant isolates were not identified in this study, but NG-MAST 1407 and penA mosaics, associated with elevated cephalosporin MICs, are circulating.

**Disclosure** No significant relationships.

---

**P638**

**SURVEILLANCE OF GONOCOCCAL INFECTION TREATMENT FAILURES 2015–2018 IN QUEBEC, CANADA**

Sylvie Venne*, Annie-Claude Labbé, Brigitte Lefebvre, Claude Fortin, Annick Trudelée, Fannie Defay, Vincent Boissonneault, Karine Bloquin, Direction de la prévention des ITSS, Ministère de la santé et des services sociaux du Québec; Département de microbiologie, infectiologie et immunologie, Université de Montréal; Laboratoire de santé publique du Québec, Institut national de santé publique du Québec; Direction des risques biologiques et de la santé au travail (DRBST), Institut national de santé publique du Québec (INSPQ), Special thanks to the public health professionals who collect all data and the clinicians who collaborate with them

Background Incident cases of gonococcal infection are increasing. Antibiotic resistance may compromise the effectiveness of treatment. In 2017, the proportion of azithromycin-resistant strains reached 31% in Quebec and a first strain non-susceptible to ceftriaxone and cefixime was detected.

**Methods** Since November 2014, public health departments are invited to report possible cases of treatment failures. Clinical and epidemiological information is collected using a standardized form for each report of gonococcal infection occurring <42 days after a previous episode in the same person. Antibacterial susceptibility testing (AST) is conducted at the